The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
Open Access
- 15 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (4), 661-666
- https://doi.org/10.1007/s12288-020-01279-8
Abstract
Systemic mastocytosis (SM) is a rare clonal disorder with multi-organ involvements and shortened life expectancy. To date, no curative treatment for SM exists. Cladribine (2-CdA) is a purine analogue showing activity against neoplastic mast cells and its use was found to be effective in some patients with SM. Nine patients (six males and three females) with advanced SM at median age of 63 years (range 33–67) who received at least one course of 2-CdA were included in a retrospective analysis. Study patients were classified as having aggressive SM (ASM; n = 7) and SM with an associated hematological neoplasm (SM-AHN; n = 2). The “C” findings were as follows: (1) absolute neutrophil count (ANC) < 1 × 109/l (n = 1) and/or hemoglobin level < 10 g/dl (n = 4) and/or platelet count < 100 × 109/l (n = 4); (2) hepatomegaly with ascites (n = 4); (3) skeletal involvement (n = 2); (4) palpable splenomegaly with hypersplenism (n = 3) and (5) malabsorption with weight loss (n = 5). Treatment consisted of 2-CdA at dose 0.14 mg/kg/day intravenously over a 2-h infusion for 5 consecutive days. Median dose per cycle was 45 mg (range 35–60). Median number of cycles was 6 (range 1–7). Overall response rate (ORR) was 66% (6/9 pts) including three partial responses and three clinical improvements. ORR was 100% and 66% for SM-AHN and ASM, respectively. Median duration of response was 1.98 years (range 0.2–11.2). At the last contact, five patients died, four have little disease activity, but remain treatment- free. 2-CdA seems to be beneficial in some patients with SM, however the response is incomplete.Keywords
This publication has 13 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribineJournal of Clinical Virology, 2017
- Efficacy and Safety of Midostaurin in Advanced Systemic MastocytosisThe New England Journal of Medicine, 2016
- Cladribine for mastocytosis: benefits and risksBlood, 2015
- Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosisBlood, 2015
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosisBlood, 2013
- In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816VExperimental Hematology, 2010
- Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectivesExpert Review of Hematology, 2010
- Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosineAmerican Journal of Hematology, 2009
- Cladribine therapy for systemic mastocytosisBlood, 2003
- Treatment of Systemic Mast-Cell Disease with CladribineThe New England Journal of Medicine, 2001